Endovascular Treatment Devices Market Size, Share and Industry Analysis Report, Regional Outlook, Growth Potential, Competitive Market Share & Forecast, 2024 – 2032

Endovascular Treatment Devices Market Size

The global endovascular treatment devices market is expected to grow tremendously from 2025 to 2034, with the increasing incidence of vascular diseases and advancements in minimally invasive techniques. As the incidence of conditions such as acute ischemic stroke, AAA, and PAD continues to rise, the use of sophisticated endovascular treatment devices is increasing globally.
 

As per the American Heart Association (AHA), in 2021, heart disease and stroke resulted in more deaths in the United States than chronic lower respiratory diseases and all forms of cancer combined. This has strongly fueled the need for sophisticated thrombectomy and neurovascular devices for safe and timely revascularization.
 

The increased prevalence of abdominal aortic aneurysms worldwide fuels demand for endovascular treatment. Endovascular aortic aneurysm repair (EVAR) has emerged as the preferred treatment due to faster recovery with reduced mortality and fewer post-operative complications than conventional open surgery.
 

In addition, the growth of the elderly population in both developed and developing countries is driving the demand for endovascular interventions – this demand is expected to grow across the forecast period.
 

The rapidly increasing prevalence of diabetes and hypertension globally is also driving the growth of endovascular devices. As the healthcare system continues to shift to value-based care and focus on patient outcomes, the outlook for minimally invasive endovascular procedures has never been brighter. It is an exciting time to invest in the endovascular industry and introduce innovative products that provide added value and improved patient outcomes.
 

Endovascular Treatment Devices Market Trends

Technological innovation, rising healthcare spending, and changing regulatory approvals are driving the market trends. Ongoing R&D is creating next-generation devices with greater precision, efficacy, and safety.
 

One of the most striking trends is the growing use of robotics and artificial intelligence (AI) in endovascular procedures.
 

In March 2025, XCath, a medical device manufacturer that specializes in driving endovascular therapy through telerobotics, introduced the addition of AI-based simulation with NVIDIA Isaac for Healthcare into its autonomous robot system. This revolutionary feature makes XCath's platform ready to deliver a high level of care for stroke and other advanced vascular conditions across the globe. Innovations such as these are improving physician control, reducing radiation exposure, and boosting treatment precision.
 

The expansion of telerobotic and remote intervention platforms is also making the headlines, particularly in rural or underserved communities. These technologies enable experts to remotely treat patients, filling the gap between access and expertise. Research centers and startups are investing heavily in creating AI-driven catheter navigation systems and image-guided technologies for accurate device deployment.
 

Bioabsorbable stents and drug-coated balloons (DCBs) are gaining popularity as a substitute for conventional metal stents. These products provide temporary scaffolding with minimization of long-term issues like restenosis. Firms are aggressively working on developing and commercializing bioresorbable materials that follow the natural healing mechanism of the body.
 

Also, wearable technologies and real-time monitoring solutions are facilitating personalized vascular health management. Wearable diagnostics integrated with mobile apps and cloud-based systems are enabling physicians to monitor patients after surgery and modify therapies in real-time, minimizing hospital readmissions and improving outcomes.
 

An increasing emphasis on hybrid operating rooms, where imaging and surgical capacities are brought together in a single environment, is making endovascular procedures more efficient and their procedural results better. The trend is specifically glaring within high-volume hospitals and cardiology care centers.
 

Finally, regulatory bodies like the U.S. FDA and the European Medicines Agency (EMA) are simplifying approval procedures for breakthrough devices. The FDA's Breakthrough Devices Program has accelerated market access for innovative endovascular solutions, facilitating innovation and speeding time-to-market.
 

Endovascular Treatment Devices Market Analysis

The cardiology segment is expected to lead the global endovascular treatment devices industry between 2025 and 2034. The rising prevalence of coronary artery disease (CAD), heart failure, and ischemic heart diseases is driving the demand for minimally invasive cardiovascular interventions. This growth highlights the urgent need for sophisticated endovascular devices for quick diagnosis, intervention, and recovery.
 

Access to new stenting technology, enhanced guidewires, and embolic protection systems is allowing for the improved treatment of heart attacks and other vascular emergencies. Widespread use of radial artery access in cardiac catheterization laboratories has lowered complications and decreased lengths of hospital stay, making endovascular cardiology procedures even more attractive.
 

Besides cardiology, the neurovascular segment is picking up, particularly in the management of ischemic stroke. Mechanical thrombectomy has become the new gold standard for large vessel occlusion patients. Growing availability of large-bore aspiration catheters, stent retrievers, and intracranial stents is driving clinical outcomes and accelerating segment growth.
 

Peripheral vascular interventions are also experiencing significant progress, with growing adoption of atherectomy devices, drug-eluting technologies, and chronic total occlusion (CTO) devices. These advancements are increasing the treatable patient population and providing physicians with greater flexibility in the treatment of challenging lesions.
 

Geographically, Europe's endovascular treatment devices market is expected to witness strong growth over the forecast period. Increasing stroke prevalence, favorable reimbursement policies, and supportive healthcare infrastructure are driving regional growth.
 

Poland, Romania, Hungary, and Bulgaria are still registering higher stroke mortality rates, and hence, there is a huge demand for efficient endovascular interventions.
 

Government-funded R&D projects like France's Agence Nationale de la Recherche's DEEP (Devices for Augmented Endovascular Navigation in Complex Pathways) project and the EU's Horizon Europe initiative are driving innovation and clinical research in vascular medicine. In addition, partnerships between medical device companies and academia are facilitating quicker translation of discoveries from the lab to the bedside.
 

Endovascular Treatment Devices Market Share

Some of the key players in the market are:

• Terumo Corporation
• Boston Scientific Corporation
• Endospan Ltd.
• Cardinal Health Inc.
• InspireMD Inc.
• Orchestra BioMed
• LifeTech Scientific Corporation
• Lombard Medical Technologies
   

These firms are heavily investing in R&D to launch next-generation devices with better biocompatibility, maneuverability, and imaging integration. Strategic partnerships with hospitals, research institutions, and health systems are facilitating the validation and commercialization of new treatment options effectively.
 

In addition, startups and new entrants are picking up speed by developing niche innovations like steerable microcatheters, bioabsorbable vascular scaffolds, and AI-powered navigation systems. Product development and entry into international markets are being driven by government grants and venture capital funding.
 

As reimbursement patterns change and regulatory environments become more conducive, competition is likely to heat up, pushing companies to differentiate on the basis of clinical evidence, user-centric design, and connected digital health platforms.
 

Endovascular Treatment Devices Market News

In August 2024, Terumo India—the Indian subsidiary of Japan-based medical technology major Terumo Corporation—launched the TREO Stent-Graft System, a cutting-edge device for Endovascular Aneurysm Repair (EVAR). Developed specifically for the treatment of infrarenal abdominal aortic aneurysms in adults with suitable anatomy, the TREO system stands out as the sole EVAR graft with both suprarenal and infrarenal active fixation.
 

In October of 2024, Terumo Medical Corp., the U.S. arm of Japan's Terumo Corp., acquired Onset Medical Corp., an Irvine, California-based company that focuses on sheath technology for minimally invasive cardiology and urology procedures.